ℹ️ This website is strictly for educational and informational purposes. We are not medical professionals and cannot provide dosage advice or medical guidance.
⚠️ Please consult with a qualified healthcare provider before using any substances.
CJC-1295 Without DAC
£12.00
RUO 🔬 A research peptide used in cell and tissue studies to explore acute GHRH receptor activation and its association with pulsatile growth hormone signalling. In preclinical models, it has been studied in relation to rapid-response pituitary cell activity.
Notice: Bacteriostatic Water - 3mL, Syringe 1ml will be added to your cart.
⚠️ Legal Notice This product is supplied strictly for laboratory research or educational use by qualified personnel. It is not for human or veterinary use, and must not be administered to living organisms. By ordering, you affirm you are 18+ and a trained researcher, and will use this material solely for in vitro or ex vivo studies.
About CJC-1295 Without DAC (RUO)
CJC-1295 Without DAC is a 30-amino-acid analog of growth hormone-releasing hormone (GHRH), identical to the active region of human GHRH(1–29) with a C-terminal amide. Lacking the Drug Affinity Complex (DAC), it exhibits rapid clearance in biological matrices, making it suitable for experiments requiring transient receptor activation.
Common Research Contexts
- 🔬 Studying acute GHRH receptor signalling in pituitary cell lines (e.g., AtT-20)
- 🔬 Modelling pulsatile vs. sustained hormone exposure
- 🔬 Supporting time-course experiments where short half-life is advantageous
- 🔬 Use as a control compound in DAC-comparison studies
RUO — Research Use Only
Always confirm suitability for your specific model system. Results may vary by tissue type and experimental design.
Typical Lab Use
| Parameter | Typical Range | Notes |
|---|---|---|
| Working concentration | 10 – 100 nM | ≈ 4.2 – 42 µg/mL (MW = 3,368.2 g/mol) |
| Models studied | Pituitary cells (AtT-20), hypothalamic slices, serum stability assays | |
| Exposure time | 15 min – 4 hours | Rapid degradation in serum; ideal for acute stimulation |
| Solubility | ≥5 mg/mL in 0.1% acetic acid | Avoid neutral or basic buffers |
Example Lab Workflow
- Culture AtT-20 cells to 80% confluency
- Starve 2 h in serum-free DMEM
- Add 50 nM CJC-1295 Without DAC
- Collect supernatant at 30, 60, 120 min for GH ELISA
📦 Product Information
| Form | White to off-white lyophilised powder |
| Purity | ≥98% (HPLC-UV) |
| Sequence | Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 |
| MW | 3,368.2 g/mol (TFA salt) |
| Endotoxin | <1.0 EU/mg |
| CoA included | Yes — batch-specific (HPLC, MS, AA analysis) |
🧊 Storage Guidance
| Form | Storage | Stability |
|---|---|---|
| Powder (unopened) | –20°C, dry, dark | 2+ years |
| Reconstituted stock | –80°C, single-use aliquots | 6+ months |
| Working solution | 4°C, in acidic buffer (pH 4.0) | Up to 24 h |
🧴 Handling Tips
- Equilibrate vial to room temperature before opening (15–20 min).
- Use 0.1% acetic acid in sterile water for reconstitution.
- Typical stock: 1–5 mg/mL — vortex gently, avoid foaming.
- Aliquot and freeze at –80°C to prevent degradation.
- Always label with “RUO — For Research Use Only”.
✅ Regulatory Notes • Complies with UK REACH as a downstream user • Not a medicinal product — for lab research only • Safe handling: wear gloves, lab coat, and eye protection • Dispose of peptide waste via licensed biological carrier
📚 Key References
-
Wikipedia — Modified GRF (1–29): structure, amino acid substitutions, and pharmacokinetics View Source
-
Journal of Clinical Endocrinology & Metabolism (2006) — Teichman et al.: Prolonged stimulation of GH and IGF‑I by CJC-1295 in healthy adults View Source
-
American Journal of Physiology (2006) — Alba et al.: Once‑daily CJC-1295 normalizes growth in GHRH knockout mice View Source
-
Journal of Clinical Endocrinology & Metabolism (2006) — Veldhuis et al.: Pulsatile GH secretion persists during continuous CJC-1295 stimulation View Source
-
PMC — Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF‑1 Levels View Source
-
PMC — Effects of GHRH Analog (Tesamorelin) on Endogenous GH Pulsatility and Insulin Sensitivity View Source
-
PMC — Sermorelin: a better approach to management of adult‑onset growth hormone insufficiency View Source
-
PMC — Beyond the androgen receptor: role of GHS in body composition in hypogonadal males View Source
-
PMC — The Safety and Efficacy of Growth Hormone Secretagogues (Review) View Source
-
PMC — GHRH Effects on Brain GABA Levels in Mild Cognitive Impairment and Healthy Aging View Source
-
PubMed — Sermorelin: review of its use in diagnosis and treatment of GH deficiency View Source
-
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) View Source
-
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections View Source
-
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) View Source
-
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route View Source
| Weight | 5 g |
|---|---|
| Dimensions | 1.55 × 3.85 mm |
Related products
Price range: £25.00 through £40.00
Select options
This product has multiple variants. The options may be chosen on the product page
